Johnson & Johnson (NYSE:JNJ) Position Trimmed by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 21.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,378 shares of the company’s stock after selling 2,228 shares during the quarter. Trueblood Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on JNJ shares. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Guggenheim upped their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Barclays cut their target price on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Finally, Bank of America reduced their target price on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday, January 17th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $173.27.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 0.7 %

Shares of JNJ opened at $148.10 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a 50-day simple moving average of $148.35 and a 200-day simple moving average of $156.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The firm has a market capitalization of $356.57 billion, a P/E ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.